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for the SF-12 were 52.7 for the physical dimension (PD) and 40.7 for the mental 
dimension (MD). The average score obtained on the BISS scale is 22.64 and a ques-
tionnaire to assess the perceived stress indicates a stress level of 19.01. At 14 days,
the decrease in waistline was 1.66 cm (p  0.001) and the symptoms score was 91 
(p  0.05). With regards to the scales dealing with QoL, average scores at D14 for
SF-12 were 53 for PD and 43.4 for MD. Improvement of the mental dimension (p 
0.02). Average score obtained on the BISS scale is 26.34 (p  0.01) Perceived stress
level was 17.9 (p  0.003). CONCLUSIONS: At the end of the 14 days, the reduction
in waist circumference is statistically signiﬁ cant. We also noted an improvement in the 
overall symptoms score; an improvement that has been conﬁ rmed by an improvement 
of all symptoms.
HEALTH CARE INTERVENTIONS – Clinical Outcomes Studies
PHC1
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OBJECTIVES: Treatment with LIPUS results in greater increases in bone density and 
greater reductions in bone gap area as compared to sham control in tibia fractures 
with NU(no progression of healing for at least four months). Fractures that do not 
heal after several months represent signiﬁ cant clinical and economic burden to health
care systems. Five to ten percent of all fractures are eventually classiﬁ ed as
nonunions[NU], fractures that fail to heal or will not heal without intervention.
Interventions include treatment by cast/brace, surgery, electrical stimulation, or low-
intensity pulsed ultrasound[LIPUS]. METHODS: Two primary effectiveness variables, 
change of bone density and gap area during treatment, were selected as surrogates for
bone healing. Abbreviated treatment period was maximum that sham treatment could 
be administered ethically. Both variables measured by blinded central reviewers from
CT-scans taken before/after termination of treatment. All adverse events recorded,
evaluated. Treatment duration was 16 weeks. Patients instructed to apply device once
daily for 20 minutes. Control (sham) devices were visually identical but did not
transmit ultrasound waves. Neither patients nor physicians could recognize shams.
RESULTS: A total of 101 patients enrolled (51 LIPUS, 50 sham), mean age 42.6 
(active) versus 45.1 years (sham). Based on log-transformed data, mean improvement 
in bone density was 1.34 (90% CI 1.14 to 1.57) times greater for patients randomized
to LIPUS compared to sham (p  0.002). A mean reduction in bone gap area also 
favored LIPUS treatment (p  0.014). CONCLUSIONS: Double-blind, intent-to-treat 
analyses demonstrated statistically signiﬁ cant superior effectiveness for LIPUS device 
compared to sham in terms of both endpoints over 16 weeks of treatment. Estimated
increase in bone density among patients randomized to LIPUS treatment was 34% 
greater than among patients randomized to sham. A signiﬁ cantly greater mean reduc-
tion in bone gap area after LIPUS treatment was also shown. Evaluation of adverse 
events showed that ultrasound therapy is safe.
HEALTH CARE INTERVENTIONS – Cost Studies
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OBJECTIVES: Socioeconomic status is associated with patients’ health behaviors,
health problems as well as the quality of care they receive. We examined data on U.
S. elderly patients undergoing major orthopedic surgery to determine whether socio-
economic status was associated with cost of care for patients with similar access to 
health care provided by Medicare. METHODS: We used the 2004–2006 Medicare 
data to identify all patients undergoing major orthopedic surgery. We used previously 
constructed and validated SESScore ™, which is a summary measure of socioeconomic 
status for each U.S. zip code, using data from the 2000 U.S. Census. We assessed the
effect of SESScore ™ on cost of care while controlling for other patient characteristics, 
and then examined the extent to which disparities in cost of care could be attributed 
to differences in hospital factors. Fixed effect models were used. RESULTS: SESScore 
™ was a signiﬁ cant predictor of cost of care for major orthopedic surgery. Comparing 
the lowest quintile of SESScore ™ to the highest, the cost difference was positive and 
signiﬁ cant (p  0.000). After further adjustment for hospital factors, the difference
was reduced. Within hospitals, there were only small differences in adjusted cost of 
care by patients’ socioeconomic status. CONCLUSIONS: When undergoing major 
orthopedic surgery, patients with a lower socioeconomic status have higher rates of 
cost of care than patients with a higher socioeconomic status, despite similar insurance 
coverage provided by Medicare.
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OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart 
problem in dogs. The inodilator pimobendan has shown to increase survival time of 
affected dogs when compared to the ACE inhibitor benazepril. The objective of this 
study was to estimate the cost-effectiveness of pimobendan compared to generic
benazepril for treatment of MMVD in dogs in Germany. METHODS: A Markov 
model was developed to calculate costs and beneﬁ ts of pimobendan and benazepril
over a 1-year time horizon in dogs with MMVD on concurrent furosemide treatment. 
The model structure allowed for a differentiation in costs and transition probabilities
between treatment start and maintenance treatment, and included the health states 
asymptomatic MMVD, symptomatic MMVD, treatment failure, euthanasia, and
sudden death. Most transition probabilities were based on randomized controlled
trials. Input-data on treatment pattern were derived from published literature, and
cost data taken from ofﬁ cial price and tariff lists (year 2008, perspective of the dog 
owner). Missing data were obtained from experts in canine cardiology. RESULTS:
Over the 1-year time horizon, mean total therapy cost per dog on pimobendan was 
€463.55 versus € 284.29 for benazepril. Mean survival was 274 days and 129 days
for dogs on pimobendan and benazepril, respectively; resulting in a cost of € 1.24 for 
each additional day of life on pimobendan. Mean costs per treatment day were lower 
with pimobendan (€ 1.69) when compared to benazepril (€ 2.20). Extensive one-way
and probabilistic sensitivity analyses conﬁ rmed the robustness of the results. CON-
CLUSIONS: Pimobendan is a cost-effective treatment of MMVD if the dog owner is
willing to pay a price below the normal range of food costs in Germany for each 
additional day of life. Lower total treatment costs for benazepril are merely attributed 
to a shorter survival, as pimobendan resulted in less costs per treatment day compared
to benazepril.
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OBJECTIVES: Myxomatous mitral valve disease (MMVD) presents a frequent heart 
problem in dogs. The objective of this study was to estimate the cost-effectiveness of 
pimobendan compared to benazepril for treatment of MMVD in dogs in Switzerland.
METHODS: A Markov model including the health states asymptomatic MMVD, 
symptomatic MMVD, treatment failure, euthanasia, and sudden death, was adapted 
to Switzerland. Costs (year 2008, perspective of the dog owner) and beneﬁ ts (life days 
gained, time without symptoms of heart failure) were calculated over a 1-year time
horizon for dogs on pimobendan or benazepril respectively, both on concurrent furo-
semide treatment. Most transition probabilities were based on randomized controlled 
trials. Missing data and input-data on treatment pattern were obtained from experts 
in canine cardiology. RESULTS: Mean survival over the 1-year time horizon was 274 
days for dogs on pimobendan versus 129 days for dogs on benazepril. Time spent
without any symptoms of heart failure was 86 days for pimobendan versus 15 days
for benazepril. Mean total therapy cost per dog on pimobendan was CHF 905.68
versus CHF 546.52 for benazepril; resulting in a cost of CHF 2.48 for each additional
day of life on pimobendan. Mean costs per treatment day were lower with pimoben-
dan (CHF 3.31) compared to benazepril (CHF 4.24). Extensive one-way and proba-
bilistic sensitivity analyses conﬁ rmed the robustness of the results. CONCLUSIONS:
Pimobendan is a cost-effective treatment of MMVD if the dog owner is willing to pay
a price within the normal range of food costs for each additional day of life. The 
results indicate a better quality of life of dogs on pimobendan, as they spent substan-
tially more time without any symptoms of heart failure compared to dogs on benaz-
epril. Lower total treatment costs for benazepril are merely attributed to a shorter 
survival, as pimobendan resulted in less costs per treatment day.
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OBJECTIVES: Hemostatic agents (HAs) are efﬁ cacious in reducing blood loss during
surgery, which may impact post-operative health care utilization and length of stay 
(LOS). The purpose of this study was to compare expected and actual LOS by choice
of HA in cardiac procedures. METHODS: Hospital data were extracted from a large 
U.S. hospital-based, service-level comparative database. Procedures conducted between 
2003 and 2006 were identiﬁ ed using principal ICD-9 codes and limited by Diagnostic
Related Groups (DRGs). Four cohorts for comparison were Floseal, Surgicelthrombin, 
Gelfoamthrombin, and other. Expected LOS was derived using 2006 Centers for
Medicare and Medicaid (CMS) geometric mean LOS by DRG and two-part regression
models were created to assess outcome. RESULTS: A total of 36,950 discharges were 
included. Floseal use was associated with signiﬁ cantly less likelihood of exceeding the 
